Leerink analyst Jonathan Chang believes ImmunoGen's successful completion of the interim analysis for the Phase III Forward I study of mirvetuximab soravtansine in platinum-resistant ovarian cancer removes a minor overhang and is an incremental positive. The analyst viewed an early futility stop as an unlikely scenario, but believes the stock has been pressured due to the uncertainty associated with the event. As such, he views the successful completion of the futility analysis as an incremental positive for the stock. The analyst reiterates an Outperform rating on ImmunoGen.